Gene test could personalize MS drug dosing
NCT ID NCT04410965
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how a common gene mutation (ABCG2) affects the levels and side effects of the MS drug teriflunomide in 82 Chinese patients. Participants took teriflunomide 14 mg daily for 24 weeks. The goal was to see if the mutation changes drug exposure and safety, which could help tailor treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- teriflunomide
- What this could lead to
- If successful, this could help doctors personalize teriflunomide dosing for Chinese MS patients based on their genetics, potentially improving safety.
- What could go wrong
- This is a small, completed Phase 4 study focused on genetic effects, not a new treatment. The results may not apply to other populations or change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number
China, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?